摘要
目的 探讨奎的平治疗难治性精神分裂症的疗效及不良反应。方法 将58例难治性精神分裂症患者随机分为奎的 平治疗组(研究组)和氯氮平治疗组(对照组),两组各29例。进行为期12w的临床治疗对照观察,于治疗前及治疗中的1、2、 4、8、12周末采用阳性与阴性症状量表和副反应量表评价临床疗效与不良反应。结果 有效率:研究组为79.3%,对照组为 82.8%,两组比较差异无显著性(P>0.05);两组治疗前后阳性与阴性症状量表总分、阳性阴性症状评分、一般病理症状评分 均无显著性差异(P>0.05)。研究组嗜睡、流涎、便秘、体重增加、心电图异常、恶心呕吐、白细胞减少等因子显著少于对照组, 差异有显著性(P<0.01或0.05)。结论 奎的平是一种治疗难治性精神分裂症的有效药物,且不良反应少而轻,可作为临床 首选药物使用。
Objective To investigate the curative effects and side-effects of quetiapine in refractory schizophrenia. Methods 58 patients with refractory schizophrenia were randomly divided into two groups and respectively treated with quetiapine and clozapine for 12 weeks .The curative effects and side-effects were evaluated with the Positive and Negative Symptoms Scale (PANSS) and Treatment Emergent Symptoms Scale(TESS). Results The effectual rates of quetiapine and clozapine were 79.3% and 82.8% respectively, there was no significant difference between them (P>0.05). But the side-effects such as somnolence, hypersalivation, constipation, weight gain, abnormal ECG, nausea, leukopenia decreased significantly. Conclusion Quetiapine was a safe and effective drug in treating refractory schizophrenia and could be a first-chosen drug.
出处
《临床心身疾病杂志》
CAS
2005年第1期31-32,共2页
Journal of Clinical Psychosomatic Diseases
